Search Main Menu Main Content
  • Change contrast :
Haute Autorité de Santé
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. Recherche
  • icone plus

  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

  • No element in selection

  • Contact

1 result

  • Active substance : pristinamycine
  • Active substance : rifampicine
  • Topics : Pancreatic and biliary tract diseases
  • Topics : Paediatrics
Filter
Topic
  • Diseases and conditions (1)
  • Plus ...
    • Respiratory tract diseases (1)
    • Plus ...
      • Pulmonary and pleural diseases (1)
    • Congenital, genetic and rare diseases (1)
    • Digestive system diseases (1)
    • Plus ...
      • Pancreatic and biliary tract diseases (1)
  • Population groups (1)
  • Plus ...
    • Paediatrics (1)
Content type
  • Practice Guidelines and Other Guides (1)
  • Plus ...
    • Practice guidelines (1)
Language
  • Français (1)
Active substance
  • acide clavulanique (1)
  • acide fusidique (1)
  • ceftazidime (1)
  • ciprofloxacine (1)
  • cloxacilline (1)
  • mezlocilline (1)
  • pristinamycine (1)
  • rifampicine (1)
  • sodium (1)
  • tazobactam (1)
  • tobramycine (1)
  • vancomycine (1)

Practice guidelines and other guides - 1 result

  • Management of patients with cystic fibrosis (pulmonary disease and infection)

    Practice guidelines - Posted on 15/1/2003 - Mis à jour le 19/7/2006
    Download abstract
    Add to my selection
Haute Autorité de Santé
Advancing quality in the fields of health and social care services

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • fr Français
  • en English
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
Nws1ya6c6m29S2V5